Clinical Trial

Disease: Sickle Cell Disease, SCD, (NCT06506461)

Disease info:

Sickle cell disease (SCD) is a group of disorders that affects haemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorder have atypical haemoglobin molecules called haemoglobin S, which can distort red blood cells into a sickle or crescent shape.

The production of haemoglobin A, which is the principle type of haemoglobin in humans, is governed by 3 genes: HBA1, HBA2, and HBB. Each haemoglobin A molecule consists of two alpha and two beta chains, and mutations in either of the HBA or the HBB genes may result in abnormal haemoglobin molecules with reduced or diminshed function. Sickle cell diseaase arises from a single point mutation in the 6th codon of the beta-globin gene (HBB), which results in a valine instead of a glutamic acid in the haemoglobin beta-chain.

Abnormal haemoglobin ultimately leads to anaemia as well as other symptoms, depending on the exact mutations present. Diseases caused by defective haemoglobin fall into a larger category of diseases known as the "haemoglobinopathies" which also include the thalassemias, a related group of diseases that are characterised by reduced or deficient rather than abnormal haemoglobin.

 

Frequency:
Sickle cell disease affects approximately 100,000 individuals in the USA and more than 3 million worldwide.
Official title:
St. Jude Autologous Genome Edited Stem Cells For Sickle Cell Disease-1 (SAGES1)
Who:

Contact 

Name: Akshay Sharma, MBBS

Phone: 866-278-5833

Email: referralinfo@stjude.org

Sponsor:

St. Jude Children's Research Hospital
 

Partners:
Locations:

Tennessee, United States

St. Jude Children's Research Hospital, Memphis, Tennessee, United States, 38105

Study start:
Dec. 1, 2024
Enrollment:
25 participants
Gene editing method:
CRISPR-Cas9
Type of edit:
Gene disruption
Gene:
Haemoglobin subunit gamma (HBG-115)
Delivery method:
Electroporation - Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Not yet recruiting

Description

Participants will receive a daily injection of plerixafor under the skin for 3-5 days to mobilize their hematopoietic stem and progenitor cells (HSPCs) into peripheral blood. About 2-4 hours after each dose of plerixafor is given, the collection of HSPCs will start via apheresis. The collected HSPCs will be sent to a lab to genetically modify them using CRISPR/Cas9.

In the lab, the researchers will take the stem cells and purify them. The stem cells will then be mixed with the CRISPR-Cas9 gRNA ribonucleoprotein (RNP) complex to change (edit) the genes in the cells and produce the new gene edited cellular product. This gene edited drug product will be frozen until ready for infusion.

Once the cellular product is ready, participants will be given Busulfan (a chemotherapy medicine) intravenously (IV) for 4 days. The thawed gene product will be given IV about 48 hours after the completion of the last dose of busulfan.

Participants will be followed for 3 years on this study. After the three years, participants will be followed for 12 more years on a long-term follow-up study.

Last updated: Dec. 28, 2024
close
Search CRISPR Medicine